Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes Care
May 19 2022 - 8:00AM
Business Wire
Leading Medical Experts to Discuss Promising
Developments on Prescription Digital Therapeutics and Nutritional
Cognitive Behavioral Therapy for Type 2 Diabetes Patients
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX),
a prescription digital therapeutics (PDT) company developing
nutritional cognitive behavioral therapy (nCBT) to address the root
causes of cardiometabolic diseases, today announced a virtual
educational webinar symposium featuring a panel of medical and
technology experts to discuss the use of nCBT delivered via
prescription digital therapeutics to combat the underlying causes
of cardiometabolic diseases like type 2 diabetes. This presentation
will focus on the recently revised American Diabetes Association
(ADA) Standard of Care guidelines which recommend digital support
tools as part of a therapy regimen.
WHEN: Wednesday, June 1, 2022 – 12:00 – 1:00 p.m. ET
WHAT: The online symposium will convene a panel of
experts to review the new ADA behavioral therapy guidelines while
looking at how nCBT works to support behavioral change in patients
with cardiometabolic diseases. Additionally, it will showcase how
PDT can offer a unique mechanism of action that enables nCBT to be
used at scale.
The panel will review and discuss recently released clinical
trial data from Better Therapeutics’ pivotal clinical trial for
BT-001, its digital therapeutic platform for type 2 diabetes.
Released earlier this year, the clinical trial demonstrated
significant reduction in A1c levels that surpassed results seen in
patients using pharmaceutical solutions alone.
The symposium will also discuss the future potential for
prescription digital therapeutics to address the ADA’s behavior
change guidelines and to improve type 2 diabetes patient
outcomes.
WHO:
Panel Chair
- Marc Bonaca, MD, MPH, Professor of Medicine and Director of
Vascular Research, University of Colorado
Moderators
- Bob Eckel, MD, Professor of Medicine, University of Colorado
and past president of American Heart Association and American
Diabetes Association
- Judy Hsia, MD, Research Professor of Medicine, University of
Colorado
Panel and Presenters:
- Hayden Bosworth, PhD, Research Professor, Department of
Medicine, Division of General Internal Medicine, Department of
Psychiatry and Behavioral Sciences, School of Nursing, Duke
University Medical Center
- Amy Bucher, PhD, Chief Behavioral Officer, Lirio
- Prapti Mehta, MD, Private Practice Psychiatrist, San Francisco,
California
- Kristin Wynholds, Chief Product Officer, Better
Therapeutics
WHERE: To attend the webinar, please register at:
bit.ly/3wpwBWA
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are
"forward-looking statements" within the meaning of the safe harbor
provisions under the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are typically
identified by words such as “plan,” “believe,” “expect,”
“anticipate,” “intend,” “outlook,” “estimate,” “forecast,”
“project,” “continue,” “could,” “may,” “might,” “possible,”
“potential,” “predict,” “should,” “would” and other similar words
and expressions, but the absence of these words does not mean that
a statement is not forward-looking. The forward-looking statements
in this press release include, but are not limited to, statements
regarding the timing and results of the ongoing trial of BT-001 in
patients with type 2 diabetes, Better Therapeutics’ plans regarding
FDA submissions, expectations related to the potential benefits of
BT-001 and CBT and their potential treatment applications, Better
Therapeutics’ plans regarding the research and advancement of its
product candidates for additional treatments, expectations related
to the interest of healthcare providers and payers in PDTs and
legislative developments affecting PDTs and the outcome of such
developments, among others. These forward-looking statements are
based on the current expectations of the management of Better
Therapeutics and are inherently subject to uncertainties and
changes in circumstances and their potential effects and speak only
as of the date of such statement. There can be no assurance that
future developments will be those that have been anticipated. These
forward-looking statements involve a number of risks, uncertainties
or other assumptions that may cause actual results or performance
to be materially different from those expressed or implied by these
forward-looking statements including: risks related to Better
Therapeutics’ business, such as the willingness of the FDA to
authorize PDTs for commercial distribution and insurance companies
to reimburse their use, market acceptance of PDTs, the risk that
the results of previously conducted studies will not be repeated or
observed in ongoing or future studies involving our product
candidates and other risks and uncertainties included under the
header “Risk Factors” in the definitive proxy statement/prospectus
filed by us on October 12, 2021.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220519005284/en/
Peter Duckler at Real Chemistry pduckler@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024